Business
Financial Results for the year ended 30 Sept 2015
Financial Results for the year ended 30 Sept 2015.
About this update from Ixico Plc
[{"type":"text","content":"\n \nRNS Number : 0876L IXICO plc 07 January 2016 \n \n\n7 January 2016\n \nFinancial Results for the year ended 30 September 2015\n \nExecuting the digital healthcare strategy \n \nIXICO plc (AIM: IXI) (\"IXICO\" or the \"Company\"), the brain health company, today announces its final results for the year ended 30 September 2015.\n \nHighlights \n \n· Long term contract award of Phase II/III global study in neurodegenerative disease\no Contract from leading global pharmaceutical company\no Highlights growing position in neuroscience clinical trial market\no Expected to run over at least seven years with a revenue value of c. $1 million per year\no Utilising TrialTracker™ and Assessa® digital technology platforms\n \n· Huntington's disease is a growing specialism\no Two existing contracts significantly expanded to c.£2.5 million\no Third contract awarded in April 2015\n \n· VirtualScopics Inc. alliance achieving commercial traction\no Two new contract awards in the year using TrialTrackerTM\no Implementation of TrialTracker™ into VirtualScopics platform completed\n \n· Financial performance underpinned by strong revenue growth* \no Revenues increased in the year to £3.1 million\no Other income increased to £1.1 million (2014: £1.0 million) giving a combined total income of £4.2 million\no Loss after tax reduced to £1.2 million (2014: £2.3 million) and loss per share reduced to 7.9p/share (2014: 10.4p/share)\no Cash of £1.9 million at 30 September 2015\n \n*2014 figures refer to the 16 months ended 30 September 2014\n \nPost year end highlights \n \no Strategic collaboration with a leading pharmaceutical company to develop and pilot Assessa® for the clinical management of Multiple Sclerosis\no Acquisition of Optimal Medicine Limited and placing of £2.7m before exp...